Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers
Abstract Omeprazole and sodium bicarbonate dry suspension are effective treatments for acid-related disorders. This study compared the bioequivalence and safety of the two formulations of omeprazole and sodium bicarbonate powder and assessed how CYP2C19 gene polymorphisms affect pharmacokinetics (PK...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-27286-5 |
| _version_ | 1797945972694712320 |
|---|---|
| author | Rui Zhang Pengpeng Guo Jinping Zhou Peixia Li Jing Wan Chunxiao Yang Jiali Zhou Yani Liu Shaojun Shi |
| author_facet | Rui Zhang Pengpeng Guo Jinping Zhou Peixia Li Jing Wan Chunxiao Yang Jiali Zhou Yani Liu Shaojun Shi |
| author_sort | Rui Zhang |
| collection | DOAJ |
| description | Abstract Omeprazole and sodium bicarbonate dry suspension are effective treatments for acid-related disorders. This study compared the bioequivalence and safety of the two formulations of omeprazole and sodium bicarbonate powder and assessed how CYP2C19 gene polymorphisms affect pharmacokinetics (PK). A single-center, randomized, single-dose, 2-sequence and 2-period crossover method was performed in forty healthy Chinese subjects. Blood samples were collected after a single dose for PK (AUC0–∞, AUC0–t, and Cmax) analysis. The concentrations of Omeprazole in human plasma were determined by HPLC–MS/MS. Besides, the gene polymorphisms of CYP2C19 were assessed by Sanger sequencing. The geometric mean ratios (90% confidence interval) [GMR (95% CI)] of Test/Reference preparation for Cmax: 95.2% (88.48%, 102.43%), AUC0–t: 97.47% (94.4%, 101.02%), AUC0–∞: 97.68% (94.27%, 101.21%) were within the range of 80.00–125.00%. The non-parametric test showed no statistical difference in Tmax between the two groups (p > 0.05). All drugs were well tolerated, no severe adverse reactions occurred, and no significant differences in adverse events between the two drugs. For CYP2C19 gene polymorphisms, the results showed that of 40 subjects, 12 subjects were extensive metabolizers, 24 were intermediate metabolizers, and 4 were poor metabolizers, the frequency of metabolic genotypes were 30%, 60%, and 10%. And the allele distributions for CYP2C19 were *1, *2, and *3 at 60%, 38.75%, and 1.25%. Both the CYP2C19 alleles and metabolic genotypes were consistent with other studies in Chinese. The results of PK parameters showed that different genotypes of CYP2C19 lead to significant differences in t1/2, AUC0–t, AUC0–∞ and Cmax, but no significant differences in Tmax in each group. At the same time, we confirmed that the PK parameters of the test and reference had no differences between the males and females. This study has shown that the pharmacokinetic parameters of the two formulations are not significantly different, which showed bioequivalence and exemplary safety. CYP2C19 gene polymorphism significantly differed in the PK parameters of omeprazole sodium bicarbonate powder. |
| first_indexed | 2024-04-10T21:03:30Z |
| format | Article |
| id | doaj.art-c0612ec4a40247c492e6fc52aba60993 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-10T21:03:30Z |
| publishDate | 2023-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-c0612ec4a40247c492e6fc52aba609932023-01-22T12:11:49ZengNature PortfolioScientific Reports2045-23222023-01-0113111010.1038/s41598-022-27286-5Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteersRui Zhang0Pengpeng Guo1Jinping Zhou2Peixia Li3Jing Wan4Chunxiao Yang5Jiali Zhou6Yani Liu7Shaojun Shi8Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Omeprazole and sodium bicarbonate dry suspension are effective treatments for acid-related disorders. This study compared the bioequivalence and safety of the two formulations of omeprazole and sodium bicarbonate powder and assessed how CYP2C19 gene polymorphisms affect pharmacokinetics (PK). A single-center, randomized, single-dose, 2-sequence and 2-period crossover method was performed in forty healthy Chinese subjects. Blood samples were collected after a single dose for PK (AUC0–∞, AUC0–t, and Cmax) analysis. The concentrations of Omeprazole in human plasma were determined by HPLC–MS/MS. Besides, the gene polymorphisms of CYP2C19 were assessed by Sanger sequencing. The geometric mean ratios (90% confidence interval) [GMR (95% CI)] of Test/Reference preparation for Cmax: 95.2% (88.48%, 102.43%), AUC0–t: 97.47% (94.4%, 101.02%), AUC0–∞: 97.68% (94.27%, 101.21%) were within the range of 80.00–125.00%. The non-parametric test showed no statistical difference in Tmax between the two groups (p > 0.05). All drugs were well tolerated, no severe adverse reactions occurred, and no significant differences in adverse events between the two drugs. For CYP2C19 gene polymorphisms, the results showed that of 40 subjects, 12 subjects were extensive metabolizers, 24 were intermediate metabolizers, and 4 were poor metabolizers, the frequency of metabolic genotypes were 30%, 60%, and 10%. And the allele distributions for CYP2C19 were *1, *2, and *3 at 60%, 38.75%, and 1.25%. Both the CYP2C19 alleles and metabolic genotypes were consistent with other studies in Chinese. The results of PK parameters showed that different genotypes of CYP2C19 lead to significant differences in t1/2, AUC0–t, AUC0–∞ and Cmax, but no significant differences in Tmax in each group. At the same time, we confirmed that the PK parameters of the test and reference had no differences between the males and females. This study has shown that the pharmacokinetic parameters of the two formulations are not significantly different, which showed bioequivalence and exemplary safety. CYP2C19 gene polymorphism significantly differed in the PK parameters of omeprazole sodium bicarbonate powder.https://doi.org/10.1038/s41598-022-27286-5 |
| spellingShingle | Rui Zhang Pengpeng Guo Jinping Zhou Peixia Li Jing Wan Chunxiao Yang Jiali Zhou Yani Liu Shaojun Shi Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers Scientific Reports |
| title | Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers |
| title_full | Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers |
| title_fullStr | Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers |
| title_full_unstemmed | Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers |
| title_short | Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers |
| title_sort | pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy chinese volunteers |
| url | https://doi.org/10.1038/s41598-022-27286-5 |
| work_keys_str_mv | AT ruizhang pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers AT pengpengguo pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers AT jinpingzhou pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers AT peixiali pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers AT jingwan pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers AT chunxiaoyang pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers AT jializhou pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers AT yaniliu pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers AT shaojunshi pharmacokineticsandbioequivalenceevaluationofomeprazoleandsodiumbicarbonatedrysuspensionsinhealthychinesevolunteers |